Mexiletine in Sporadic Amyotrophic Lateral Sclerosis (SALS)

Summary

The purpose of this research is to find out if mexiletine is safe and effective in people with Amyotrophic Lateral Sclerosis (ALS). In this trial, participants will be taking either 300 milligrams per day of mexiletine, 900 milligrams per day of mexiletine or placebo (non-active study drug). The safety and efficacy of these doses will be compared to see if one dose is better than the other.

Timeline

Start

2013-07

Primary completion

2014-08

Completion

2014-08

Drugs

Indications